HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Helen of Troy Q2

This article was originally published in The Rose Sheet

Executive Summary

Sea Breeze and Brut brands generated double-digit sales growth in the quarter, company announces during Oct. 11 earnings call. However, personal care net revenues declined 14.8% to $100.9 mil., due to "pressures to lower prices, additional competition on selected items and additional costs associated with trade promotions," firm says. Division may rebound next year with the launch of Sea Breeze Naturals, a line that will be targeted to older customers rather than the brand's traditionally younger audience, Helen of Troy notes. Company adds that sales of Brut in Mexico have been "very positive" since launching new products in the region (1"The Rose Sheet" April 25, 2005, p. 9). Second quarter net sales declined 7.7% to $130.4 mil., while net earnings fell 49.9% to $9.5 mil., impacted by challenging economic conditions and weak performance by personal care segment, firm says. Fiscal 2006 (ending Feb. 28) sales are expected to be in the range of $575 mil.-$590 mil., versus previous guidance of $615 mil.-$640 mil, according to Helen of Troy...

You may also be interested in...



Orchard’s Gene Therapy Under Fast-Track Review At EMA

A handful of new products are under review at the European Medicines Agency. Orchard Therapeutics' gene therapy application will be fast-tracked; Roche's filing for its new flu treatment will not.

Ipsen’s Palovarotene Hit By FDA Clinical Hold

The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.

Venture Funding Deals: Sumitomo Alliance With Roivant Takes Shape

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.

UsernamePublicRestriction

Register

RS013432

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel